Circulating Tumor DNA for Predicting Occult Metastases in Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma

Circulating Tumor DNA for Predicting Occult Metastases in Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma - ctDNA for Predicting Occult Metastases in Potentially Resectable PDAC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054546

Enrollment

130

Registered

2024-06-02

Start date

2019-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resectable and borderline resectable pancreatic ductal adenocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically or cytologically proven diagnosis of PDAC 2) Patients with R and BR PDAC

Exclusion criteria

Exclusion criteria: 1) Patients with pathologically carcinoma in situ or complete response by neoadjuvant therapy 2) Patients with active cancer

Design outcomes

Primary

Measure	Time frame
Association of preoperative ctDNA and occult metastases	—

Secondary

Measure	Time frame
Association of preoperative ctDNA and prognosis	—

Countries

Japan

Contacts

Public ContactTakeshi Murakami

Sapporo Medical University Department of Surgery, Surgical Oncology and Science

murakami.takeshi@sapmed.ac.jp0116112111

Outcome results